[go: up one dir, main page]

ES2078319T3 - Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras. - Google Patents

Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.

Info

Publication number
ES2078319T3
ES2078319T3 ES90312053T ES90312053T ES2078319T3 ES 2078319 T3 ES2078319 T3 ES 2078319T3 ES 90312053 T ES90312053 T ES 90312053T ES 90312053 T ES90312053 T ES 90312053T ES 2078319 T3 ES2078319 T3 ES 2078319T3
Authority
ES
Spain
Prior art keywords
treatment
ulcers
aldosa
compositions containing
reductase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90312053T
Other languages
English (en)
Inventor
Kiichi Sawai
Masayasu Kuroni
Kazumasa Nakano
Makoto Sato
Noboru Kuboyama
Takashi Ito
Yoshiya Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanwa Kagaku Kenkyusho Co Ltd
Original Assignee
Sanwa Kagaku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co Ltd filed Critical Sanwa Kagaku Kenkyusho Co Ltd
Application granted granted Critical
Publication of ES2078319T3 publication Critical patent/ES2078319T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA PREPARACION TERAPEUTICA PARA EL TRATAMIENTO DE LAS ULCERAS DE LA PIEL, LABIALES, INTRAORALES Y DEL APARATO DIGESTIVO, DE LAS HERIDAS POR AGENTES CORROSIVOS, DE LAS ULCERAS POR DECUBITO, QUEMADURAS, ULCERAS POR CONGELACION Y ESCLERODERMA, QUE CONTIENE COMO INGREDIENTE PRINCIPAL UN COMPUESTO QUE TIENE UNA ACTIVIDAD INHIBITORIA DE LA ALDOSA REDUCTASA, Y EL CUAL PUEDE ACELERAR EL METABOLISMO DE LA DERMIS. LOS COMPUESTOS MAS UTILIZADOS SON DERIVADOS DE LA HIDANTOINA OPTICAMENTE ACTIVOS.
ES90312053T 1990-01-12 1990-11-02 Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras. Expired - Lifetime ES2078319T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005773A JPH03215435A (ja) 1990-01-12 1990-01-12 アルドース還元酵素阻害剤を主成分とする潰瘍治療剤

Publications (1)

Publication Number Publication Date
ES2078319T3 true ES2078319T3 (es) 1995-12-16

Family

ID=11620439

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90312053T Expired - Lifetime ES2078319T3 (es) 1990-01-12 1990-11-02 Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.

Country Status (7)

Country Link
US (1) US5155125A (es)
EP (1) EP0437025B1 (es)
JP (1) JPH03215435A (es)
AT (1) ATE127344T1 (es)
DE (1) DE69022206T2 (es)
DK (1) DK0437025T3 (es)
ES (1) ES2078319T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661293A3 (en) * 1993-12-29 1999-05-19 Sanwa Kagaku Kenkyusho Co., Ltd. Protein having cell growth-stimulating and macrophage chemotactic actions, preparative method therefor and use thereof
DE69519219T2 (de) * 1994-12-28 2001-02-22 Sanwa Kagaku Kenkyusho, Co. Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
WO2006022450A1 (ja) * 2004-08-26 2006-03-02 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
AU2008230949B2 (en) 2007-03-23 2013-05-30 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
JP5976010B2 (ja) * 2010-12-23 2016-08-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Ｃｏｐｄを処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
EP0006352A1 (en) * 1978-06-15 1980-01-09 Beecham Group Plc Hydantoins and thiohydantoins, process for their preparation and pharmaceutical compositions containing them
CH638975A5 (fr) * 1979-07-27 1983-10-31 Prebuilt Ets Composition medicamenteuse pour le traitement des ulceres gastro-duodenaux.
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
DK0384416T3 (da) * 1989-02-22 1994-02-28 Sanwa Kagaku Kenkyusho Co Farmaceutisk sammensætning indeholdende hydantoinderivat

Also Published As

Publication number Publication date
ATE127344T1 (de) 1995-09-15
DE69022206D1 (de) 1995-10-12
EP0437025B1 (en) 1995-09-06
DE69022206T2 (de) 1996-04-18
US5155125A (en) 1992-10-13
EP0437025A3 (en) 1992-02-26
DK0437025T3 (da) 1995-12-18
JPH03215435A (ja) 1991-09-20
EP0437025A2 (en) 1991-07-17

Similar Documents

Publication Publication Date Title
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
AU549481B2 (en) Hair growing agent
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
MX9307185A (es) Derivados de carboxilato de indol que inhiben la biosintesis del leucotrieno y composiciones farmaceuticas que los contienen.
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
DE69818294D1 (de) Oxazolidinone derivate und pharmazeutische zusammensetzungen
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
EP1142573A4 (en) Antibacterial medicinal compositions
ES2078319T3 (es) Composiciones que contienen inhibidores de aldosa reductasa para el tratamiento de ulceras.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
NO971743D0 (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE22555T1 (de) Mercaptoessigsaeure und 3-mercaptopropionsaeureamidderivate fuer ihre verwendung bei der therapeutischen behandlung von menschlichen oder tierischen koerpern, einige neue derivate und diese enthaltende pharmazeutische zusammensetzungen.
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
DE69727268D1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
BR9908452A (pt) Composição fungicida que compreende uma benzoilfeniluréia
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 437025

Country of ref document: ES